AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines
2 March 2020 07:00 GMT
AstraZeneca completes divestment agreement with
Atnahs Pharma for established hypertension medicines
AstraZeneca today announced that it has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).
Under the terms of the agreement, AstraZeneca has received a payment of $350m from Atnahs. The Company may also receive future sales-contingent payments of up to $40m between 2020 and 2022. The upfront payment will be reported in AstraZeneca's financial statements within Other Operating Income & Expense in the first quarter of 2020.
Inderal (propranolol) is a beta-blocker and is predominantly used to treat tremors, angina, hypertension, arrhythmias, and other heart or circulatory conditions. It is also used to reduce the severity and frequency of migraine.
Tenormin and Tenoretic
Tenormin (atenolol) is a beta-blocker that is used to treat angina and hypertension, as well as certain kinds of arrhythmias. It is also used to lower the risk of death after a heart attack. Tenoretic is a fixed-dose combination of atenolol (beta-blocker) and chlorthalidone (diuretic), used to treat high blood pressure.
Zestril and Zestoretic
Zestril (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease. Zestril may also be used to improve survival after a heart attack. Zestoretic is a fixed-dose combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (diuretic) used to treat hypertension.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
|Gonzalo Viña||+44 203 749 5916|
|Rob Skelding||Oncology||+44 203 749 5821|
|Rebecca Einhorn||Oncology||+1 301 518 4122|
|Matt Kent||BioPharmaceuticals||+44 203 749 5906|
|Angela Fiorin||BioPharmaceuticals||+44 1223 344 690|
|Jennifer Hursit||Other||+44 203 749 5762|
|Christina Malmberg Hägerstrand||Sweden||+46 8 552 53 106|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||+44 203 749 5712|
|Henry Wheeler||Oncology||+44 203 749 5797|
|Christer Gruvris||BioPharmaceuticals (Cardiovascular, Metabolism)||+44 203 749 5711|
|Nick Stone||BioPharmaceuticals (Renal) Environmental, Social and Governance||+44 203 749 5716|
|Josie Afolabi||BioPharmaceuticals (Respiratory)||+44 203 749 5631|
|Tom Waldron||Other medicines||+44 7385 033 717|
|Craig Marks||Finance Fixed income||+44 7881 615 764|
|Jennifer Kretzmann||Corporate access Retail investors||+44 203 749 5824|
|US toll-free||+1 866 381 72 77|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.